Earnings call transcript: Philips Q2 2025 sees steady growth, new launches

Royal Philips (PHIA) reported Q2 2025 earnings with comparable sales growth of 1% and a 6% increase in order intake, driven by strategic product launches and operational efficiencies. Adjusted diluted EPS rose 20% to €0.36, and the adjusted EBITDA margin improved by 130 basis points to 12.4%. The company reiterated its full-year comparable sales growth outlook of 1-3% but raised its adjusted EBITDA margin forecast to 11.3-11.8% and free cash flow guidance to €0.2-€0.4 billion, partly reflecting lower tariff impacts. Despite a slow recovery in China, Philips highlighted strong demand in North America and growth geographies, alongside significant productivity savings, positioning it for accelerated growth in the second half and beyond.

Analysis

Royal Philips (PHIA) reported a resilient Q2 2025, with comparable sales growing 1% and order intake increasing 6%, indicating strong underlying demand. Adjusted diluted EPS from continued operations rose 20% year-over-year to €0.36, while the adjusted EBITDA margin improved by 130 basis points to 12.4%, driven by strategic product launches and operational efficiencies. Key innovations like the Azurion platform, BlueSeal MR, and AI-powered CT 5300 contributed to strong gross margin expansion and order growth across Diagnosis & Treatment. Philips also highlighted significant quality improvements, reducing field actions by 20% year-to-date, and improved supply chain service levels to an all-time high of 86%.

The company reiterated its full-year comparable sales growth outlook of 1-3% but raised its adjusted EBITDA margin range to 11.3-11.8% and free cash flow guidance to €0.2-€0.4 billion, reflecting improved tariff expectations and ongoing productivity savings. Philips has achieved €2.1 billion in productivity savings since 2023, with €344 million year-to-date, targeting €800 million for 2025. This operational discipline, alongside strong order book momentum, underpins confidence in a stronger second-half performance.

Despite a slow recovery in the Chinese market, particularly in Personal Health where destocking is complete, and medical equipment sales remain cautious, strong demand in North America and other growth geographies is offsetting regional weakness. Philips is actively mitigating tariff impacts, with a reduced net impact of €150-€200 million for 2025, though Q3 EBITDA margin is expected to decline due to tariff timing. The upcoming Capital Markets Day in February 2026 will outline a strategy targeting mid-single-digit growth and mid-to-high teens margins beyond 2025, building on improved quality and supply chain resilience.

Key Decisions for Investors

• Investors should consider PHIA's improved full-year adjusted EBITDA and free cash flow outlooks, driven by operational efficiencies and innovation, as indicators of strengthening fundamentals.
• Monitor the impact of tariffs on Q3 EBITDA margins and the pace of recovery in the Chinese market, as these remain key near-term variables.
• Evaluate the strategic vision to be presented at the February 2026 Capital Markets Day for clarity on long-term growth and margin expansion targets, particularly the trajectory towards mid-single-digit growth and mid-to-high teens margins.